Clinical trial · no report yet · Phase 2
IMMUNOPLANT
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
- NCT06376526 ↗
- Recruiting
- Dickran Kazandjian, MD
- 23 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 13 | |
| X threads | 6 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial cOmbination Therapy to Pursue Deeper Responses With Linvoseltamab ANd Delay Transplant
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab
- Arms
- Linvoseltamab Group · Experimental
- Enrollment
- 150 (estimated)
- Primary outcomes
- Minimal Residual Disease (MRD) Negativity Rate
- Sponsor
- Dickran Kazandjian, MD with Regeneron Pharmaceuticals
- Start
- Aug 21, 2024
- Primary completion
- Aug 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06376526 · updated Aug 18, 2026